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in-person instruction on at-home knee exercise. The primary outcome
measure was a composite score on the Western Ontario McMaster
University Osteoarthritis Index (WOMAC; 100 points), which assessed
knee pain, function and stiffness on a per subject basis. The secondary
outcome was the Knee Pain Scale (KPS) which assessed knee pain severity
and frequency on a per knee basis; both were done at baseline, 5, 9
12, 26 and 52 weeks. Procedure-related opioid medication use, subject
satisfaction and adverse events were also assessed.
Results: Analysis was by intention to treat. No signiﬁcant baseline
differences existed between the groups in age, gender, pain duration,
body mass index or WOMAC scores. 89 subjects (57±8.3 years old,
59 female) with moderate to severe KOA received an average of 4.3±0.7
prolotherapy injection sessions over a 17-week treatment period. All
groups reported improved composite WOMAC scores compared to
baseline status (p < 0.01) at 52 weeks. However, WOMAC scores for
prolotherapy subjects, adjusted for gender, age and body mass index
showed signiﬁcantly greater improvement onWOMAC score at 52 weeks;
15.32±3.52 points for prolotherapy compared to 7.68±3.41 points for
saline injection (p < 0.05) and 8.25±3.33 points for exercise (p< 0.05).
The improvement by prolotherapy subjects exceeded minimal clinical
important difference. KPS scores of prolotherapy subjects showed similar
improvement per injected knee compared to baseline status (p < 0.001)
and controls (p < 0.05). Prescribed post-procedure opioid medication
resulted in rapid diminution of prolotherapy injection pain. Satisfaction
with prolotherapy was high and there were no adverse events.
Conclusions: Prolotherapy resulted in safe, signiﬁcant, sustained
improvement of pain, function and stiffness scores compared to blinded
saline injections and at-home exercises in knee osteoarthritis.
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A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,
MULTICENTER STUDY OF rhFGF18 ADMINISTERED INTRAARTICULARLY
USING SINGLE OR MULTIPLE ASCENDING DOSES IN PATIENTS WITH
PRIMARY KNEE OSTEOARTHRITIS (OA), SCHEDULED FOR TOTAL KNEE
REPLACEMENT
L.E. Dahlberg1, K. Flechsenhar2, D. Dreher2, S. Gouteux2, J.S. Jurvelin3.
1Lund Univ., Malmo¨, Sweden; 2Merck Serono S.A. (an afﬁliate of Merck
KGaA, Darmstadt, Germany), Geneva, Switzerland; 3Univ. of Eastern
Finland, Kuopio, Finland
Purpose: No approved disease-modifying OA drugs (DMOAD) are
available. Use of a chondrocyte-targeted growth factor is a promising
approach with the potential to induce chondrocyte proliferation, increase
matrix production and promote cartilage repair. This Phase I study
evaluated the local and systemic acute safety of recombinant human
ﬁbroblast growth factor 18 (rhFGF18) intraarticular (i.a.) injection,
after single ascending dose (SAD) and multiple ascending dose (MAD)
regimens in candidates for total knee replacement (TKR) surgery. As
secondary objectives, effects of rhFGF18 on systemic biomarkers and
exposure were evaluated. Tertiary objectives were to assess: effect of
rhFGF18 on knee cartilage in selected regions of interest by MRI and
X-ray; cartilage structure and absence/presence of cartilage proliferation
from samples taken during TKR surgery; effect of rhFGF18 on OA
symptoms in the target knee. An exploratory objective was to evaluate
biomechanical properties of cartilage taken during TKR surgery.
Methods: Eligible patients were ≥40y with primary femorotibial knee
OA, who were candidates for TKR surgery (planned ≥2 weeks after
anticipated last injection of study drug); stable oral OA treatment was
permitted. Patients received rhFGF18 or placebo, randomized 3:1 per
cohort, injected i.a. into the target knee once (SAD) or once weekly for
3 weeks (MAD). SAD cohorts received 3mg, 10mg, 30mg, 100mg or 300mg;
MAD cohorts received 10mg, 30mg, 100mg, 300mg or highest tolerated
dose. Follow-up and safety reviews occurred before each dose escalation.
All subjects had ﬁnal review 24 weeks after ﬁrst injection. Unconﬁned
compression testing (dynamic and equilibrium modulus) and histological
analysis (modiﬁed Mankin scoring) were conducted for cartilage taken
during TKR surgery.
Results: In SAD cohorts, 25 patients received rhFGF18; 8 received
placebo. In MAD cohorts, 30 patients received rhFGF18; 10 received
placebo. Age range 48.5–87.1 y; BMI range 21.1–46.8 kg/m2. No
local/systemic acute safety concerns emerged, no subjects discontinued
treatment prematurely, no adverse events (AE) led to discontinuation.
Two deaths were reported: 1 patient (MAD 30mg) died of pulmonary
embolism 2 days after TKR surgery (considered likely to be unrelated to
study drug); 1 patient (MAD placebo) died from myocardial infarction
3 months after his last dose of study drug (considered unrelated
to study drug). No pattern was evident among the 8 other serious
AE (all considered unrelated to study drug). Acute inﬂammatory
reactions were slightly more common in 300mg rhFGF18-treated groups.
Treatment emergent AE did not increase in treatment vs. placebo groups.
No systemic exposure to rhFGF18 or antibodies against FGF18 were
detected. Systemic biomarkers of cartilage and bone metabolism, and
inﬂammation, showed no systemic effect of rhFGF18. Although the study
was not designed to demonstrate efﬁcacy, cartilage samples obtained
during TKR surgery suggested chondrocyte proliferation, improved
histological grading and improvement in biomechanical properties after
rhFGF18. In the 30 patients evaluated with MRI there was a suggestion
of increased cartilage volume, especially in the medial femorotibial
compartment. No changes were seen on X-ray. Improvement of OA
symptoms occurred in both placebo and rhFGF18-treated groups.
Conclusions: These Phase I results suggest no local or systemic acute
safety concerns with rhFGF18 i.a. single or multiple injections. The
proportion of patients experiencing ≥1 AE was not increased in rhFGF18
groups. No systemic exposure was detected after injection. Cartilage
samples obtained during TKR surgery suggest that rhFGF18 elicits an
anabolic response in late-stage OA. MRI ﬁndings showed a positive trend,
although longer observation with more patients is required to conﬁrm
drug effects. These results are encouraging for further investigation of
rhFGF18 as a potential DMOAD.
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IRON OVERLOAD AND HEMOCHROMATOSIS (HFE) MUTATION
CORRELATE WITH CLINICAL OUTCOMES IN AN OSTEOARTHRITIS
COHORT
L. Kennish1, M. Attur1, X. Huang1, Y. Lai2, C. Liu2, S. Krasnokutsky1,
J. Samuels1, S.B. Abramson1. 1NYUHosp. for Joint Diseases-Rheumatology,
New York, NY, USA; 2NYUHosp. for Joint Diseases-Orthopedics, New York,
NY, USA
Purpose: Iron may be a contributing risk factor for osteoarthritis (OA)
development – increased iron is found in OA synovial ﬂuid and is
cytotoxic towards chondrocytes. Additionally, patients with hereditary
hemochromatosis develop an OA phenotype that is associated with
higher ferritin levels. We examined the hypothesis that serum ferritin
is elevated in patients with knee OA and that levels of ferritin correlate
with OA severity.
Methods: The study included 150 patients with symptomatic knee OA
(patients were diagnosed by ACR criteria with a WOMAC score >125)
and 21 controls who were enrolled in a 2 year longitudinal study.
Exclusion criteria were steroid use, inﬂammatory arthritis, infection,
diabetes, hepatic/renal disease, or heart failure. Baseline clinical (age,
gender, BMI, WOMAC pain score) and radiographic characteristics (KL
score) were obtained. Cross sectional peripheral blood samples were
analyzed for serum ferritin by ELISA. Plasma PGE2 and COMP fragments
were measured by ELISA and PCR based HFE genotyping performed on
patients and controls. Statistical analysis included ANOVA and student’s
t-test.
Results: Ferritin was measured in 129 OA patients with mean age
65 years (35% men), BMI 26.5 and, in those who had radiographic scoring,
KL score 0–2 (48) and 3–4 (48), and 20 controls with mean age 56 years
(55% men), and BMI 26.5. Men and women with OA had higher average
ferritin than those without OA (one way ANOVA, p =0.008; men: 71.06
vs. 40.42ng/ml, p = 0.01; women: 42.57 vs. 32.98ng/ml, p=ns). Ferritin
levels greater than 100ng/ml were observed in 13% of patients with OA,
and in 0% of controls. OA patients had higher frequency of homozygous
HFE gene mutation C282Y/C282Y (2.29%) compared to controls (0%)
and published controls (0.26%, z=3.2). Higher ferritin levels positively
correlated with worsening KL scores in the total OA population (KL
0–2: 38.28 vs. KL 3–4: 62ng/ml, p = 0.02) and in men with OA (KL
0–2 45.03 vs. KL 2–4: 91.69ng/ml, p = 0.04). Also associated with higher
ferritin were increasing age, BMI, and WOMAC pain scores and the
HFE C282Y/C282Y mutation. PGE2 was elevated in OA patients (160.2
vs. 69.3 ng/ml, p < 0.001) and in those with higher ferritin (p = 0.05).
Similarly, COMP fragments was also elevated in OA patients (286.7 vs.
109.9 ng/ml, p = 0.03) and in those with higher ferritin (p = 0.05).
Conclusions: Selected patients with symptomatic knee OA have
increased ferritin compared to controls, as well as an increased incidence
of the C282Y/C282Y HFE gene mutation. Higher levels of ferritin in OA are
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independently associated with OA severity (KL score), WOMAC pain and
elevations of biomarkers – PGE2 and COMP fragments. Our data suggest
that increased iron (ferritin levels) may promote cartilage damage in
patients with knee OA and merits further investigation as a biomarker
of disease severity and progression.
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SAFETY AND EFFICACY OF NSAIDs IN ELDERLY ARTHRITIS PATIENTS:
A SUBGROUP ANALYSIS
H. Kellner1, M. Essex2, C. Li3. 1Div. of Rheumatology, Ctr. for Inﬂammatory
Joint Diseases, Munich, Germany; 2Pﬁzer Inc, New York, NY, USA; 3Pﬁzer
Inc., New York, NY, USA
Purpose: As increasing age is a well-known risk factor for gastrointestinal
(GI) adverse events and may contribute to reduced compliance and
discontinuation of therapy, we set out to compare the safety and efﬁcacy
of celecoxib vs diclofenac slow release (SR) plus omeprazole in elderly
patients with arthritis.
Methods: Patients aged ≥65 years, with osteoarthritis and/or rheumatoid
arthritis at increased GI risk who participated in the CONDOR trial
(Celecoxib vs Omeprazole and Diclofenac in Patients With Osteoarthritis
and Rheumatoid Arthritis) were included in this subgroup analysis. The
CONDOR trial was a 6-month, prospective, double-blind, randomized
clinical trial of celecoxib vs omeprazole and diclofenac SR. Eligible
patients were expected to need nonsteroidal anti-inﬂammatory drugs
(NSAID) therapy for at least 6 months; aspirin or antiplatelet users
were excluded. Patients were Helicobacter pylori negative. The primary
end point was a composite of clinically signiﬁcant upper and lower GI
events adjudicated by an independent blinded expert committee and
analyzed using a life-table method. Patients were randomized to either
celecoxib 200mg bid or diclofenac SR 75mg bid plus omeprazole 20mg
qd. Follow up visits were at 1, 2, 4, and 6 months from baseline. Efﬁcacy
was determined by Patients’ Global Assessment of Arthritis at each visit.
Results: 2446 patients aged ≥65 years comprised the intent-to-treat
population (n =1219 celecoxib; n = 1227 diclofenac SR). Mean (SD) age
was 70.4 (4.5) years for both arms; 83.0% of celecoxib and 80.8% of
diclofenac SR patients were female. The majority of patients were
white (54.1% celecoxib; 52.2% diclofenac SR). The difference between
the 2 incidence proportions of adjudicated primary GI end points in
patients aged ≥65 years, controlling for region, history of gastroduodenal
ulceration, and time-block was statistically signiﬁcant (odds ratio, 6.27;
P < 0.0001 favoring celecoxib). 76.9% of celecoxib and 72.0% of diclofenac
SR patients completed the study. Among those treated, 9.5% and 14.3%
of patients, respectively, discontinued treatment for reasons related to
study drug, and there were 2 deaths in the celecoxib arm and 1 in the
diclofenac SR arm. Patients’ Global Assessment of Arthritis was 3.2±0.7
at baseline and 2.4±0.8 at Month 6 for both celecoxib and diclofenac SR,
respectively. Similar percentages of patients rated efﬁcacy at good/very
good at baseline and Month 6 for celecoxib (10.5%, 55.9%) and diclofenac
SR (10.6%, 56.4%). Least squares mean (SE) at Month 6 (last observation
carried forward) was 2.539 (0.034) and 2.521 (0.033) for celecoxib and
diclofenac SR (P=NS), respectively.
Conclusions: The results of the CONDOR trial, in which celecoxib was
superior to diclofenac SR plus omeprazole in reducing the risk of clinical
outcomes across the entire GI tract, were conﬁrmed in a subgroup
analysis of patients ≥65 years. The safety and efﬁcacy of both treatments
was comparable in this population. These data may help physicians make
more informed decisions in treating elderly patients with arthritis.
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SAFETY AND EFFICACY OF RETREATMENT WITH A BIOENGINEERED
HYALURONATE FOR PAINFUL OSTEOARTHRITIS OF THE KNEE: RESULTS
OF THE OPEN-LABEL EXTENSION STUDY OF THE FLEXX TRIAL
R.D. Altman1, J.E. Rosen2, D.A. Bloch3, H.T. Hatoum4. 1UCLA, Agua Dulce,
CA, USA; 2New York Hosp., Queens, NY, USA; 3Stanford Univ., Stanford, CA,
USA; 4Univ. of Illinois, Chicago, IL, USA
Purpose: Intra-articular (IA) injection of hyaluronate (HA) has been
shown to be safe and effective for relieving pain in patients with
osteoarthritis (OA) of the knee and is recommended for patients who
cannot be effectively managed with non-pharmacologic interventions or
simple analgesics. Although many studies support the safety and efﬁcacy
of single course IA-HA injections, fewer trials have evaluated the risks and
beneﬁts of repeated series of injections. This 26 week Extension Study of
the FLEXX Trial was conducted to evaluate the safety of repeated intra-
articular (IA) injections of Euﬂexxa® (1% sodium hyaluronate; IA-BioHA)
for painful knee osteoarthritis (OA).
Methods: Participants who completed the randomized, double-blind,
26-week FLEXX Trial and who elected to participate in the Extension
Study received asecond series of3 weekly IA-BioHA injections and were
followed for an additional 26 weeks. Adverse events (AEs) were recorded
and the effect of treatment on knee pain was measured following a 50-
foot walk test using a 100mm visual analog scale (VAS). The 3 subscales
of WOMAC, OARSI responder rate, Patient Global Assessment, SF-36, and
intake of rescue medication was also evaluated.
Results: TheFLEXX Trial included 588 subjects with painful knee OA
who received 3 weekly IA injections of either BioHA or buffered saline
(IA-SA). Results from the FLEXX Trial showed that IA-BioHA decreased
mean pain 100mm visual analog scale (VAS) scores immediately after
a 50-foot walk test by −25.7mm versus −18.5mm for the IA-SA group.
Both treatments were well tolerated with about 1% of subjects in each
group reporting injection site reactions.
The Extension Study included 433 subjects, 219 who received IA-BioHA
and 214 who received IA-SA during the FLEXX Trial. Safety results from
the Extension Study indicate that 43.4% (188/433) of subjects had AEs,
of which 4.8% (21/433) were deemed treatment-related AEs. Two AEs
in the Extension study led to discontinuation, and no joint effusion was
reported. Patients who continued with IA-BioHA in the Extension Study
maintained their improvement from baseline, with an average further
reduction in pain VAS score of −3.5mm. Patients initially treated with
IA-SA in the FLEXX Trial also had a reduction in pain VAS score of
−9.0mm. The OMERACT-OARSI responder rate for all subjects was 75.3%
at the completion of the Extension Study. WOMAC Pain, Stiffness, and
Disability scores decreased by 47.2%, 42.5%, and 44.1%, respectively. The
Patient’s Global Assessment improved an additional −8.1mm and there
were 15.2% and 15.7% improvements for SF-36 physical functioning and
bodily pain scores, respectively, from the beginning of the FLEXX Trial to
the end of the Extension Study. Acetaminophen use was reduced from
14.6 to 9.5 tablets per week, representing an overall 34.9% reduction
from the beginning of the FLEXX Trial.
Conclusions: Repeated injections of IA-BioHA were effective, safe, and
well-tolerated, and were not associated with an increase in AEs such
as synovial effusions. Additional symptom improvements during the
Extension Study were noted for subjects who received either IA-BioHA
or IA-SA during the FLEXX Trial.
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A PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF A
NOVEL, PROPRIETARY, NANO-FORMULATED ORAL DICLOFENAC
S. Daniels1, G. Manvelian2, A. Gibofsky3. 1Premier Res. Group, Austin, TX,
USA; 2Independent Clinical Res. Consultant, Poway, CA, USA; 3Hosp. for
Special Surgery, New York, NY, USA
Purpose: Nonsteroidal anti-inﬂammatory drugs (NSAIDs) are a common
class of medication taken for acute arthritic pain. However, associated
adverse events (AE) have prompted the development of new
formulations that minimize AEs and maintain efﬁcacy. The purpose
of this clinical study was to evaluate the analgesic efﬁcacy and
safety of an investigational, proprietary, nano-formulated, oral diclofenac
(diclofenac-N) compared with placebo in subjects with acute dental
pain.
Methods: This was a phase-2, multisite, randomized, double-blind,
single-dose, parallel-group, active- and placebo-controlled study. In total,
200 subjects who were 18–50 years of age, had extraction of ≥2 third
molars (at least one of which had to be a fully or partially impacted
mandibular third molar), and experienced moderate to severe pain
intensity within 6 hours after surgery were enrolled. Subjects received
either diclofenac-N 35mg or 18mg, celecoxib 400mg, or placebo. The
primary efﬁcacy variable was the sum of total pain relief (TOTPAR) over
0–12 hours (TOTPAR-12) after Time 0. Higher scores indicated better
pain relief. TOTPAR-8 and TOTPAR-4 were also evaluated.
Results: Diclofenac-N was signiﬁcantly (p < 0.001) better than placebo
for TOTPAR-12. Mean±SD TOTPAR-12 values for diclofenac-N 35mg,
diclofenac-N 18mg, celecoxib 400mg, and placebo were 16.81±12.76,
17.76±13.76, 14.61±15.05, and 5.65±11.53, respectively. TOTPAR-4 and
TOTPAR-8 values for diclofenac-N 35mg and diclofenac-N 18mg
demonstrated comparable results when compared to placebo. The
difference in time-to-onset of analgesia between each treatment
